NASDAQ:FOMX - Foamix Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.22 -0.03 (-0.92 %)
(As of 04/25/2019 04:00 PM ET)
Previous Close$3.25
Today's Range$3.16 - $3.25
52-Week Range$3.13 - $7.60
Volume247,300 shs
Average Volume344,752 shs
Market Capitalization$175.06 million
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Receive FOMX News and Ratings via Email

Sign-up to receive the latest news and ratings for FOMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FOMX
CUSIPN/A
Phone972-8931-6233

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.60 million
Book Value$1.70 per share

Profitability

Net Income$-74,160,000.00
Net Margins-2,062.95%

Miscellaneous

Employees80
Market Cap$175.06 million
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions

What is Foamix Pharmaceuticals' stock symbol?

Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."

How were Foamix Pharmaceuticals' earnings last quarter?

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) issued its quarterly earnings results on Wednesday, November, 7th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.07. The specialty pharmaceutical company earned $0.87 million during the quarter, compared to analysts' expectations of $1.10 million. Foamix Pharmaceuticals had a negative return on equity of 103.92% and a negative net margin of 2,062.95%. View Foamix Pharmaceuticals' Earnings History.

When is Foamix Pharmaceuticals' next earnings date?

Foamix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Foamix Pharmaceuticals.

What price target have analysts set for FOMX?

4 brokers have issued 1-year target prices for Foamix Pharmaceuticals' stock. Their forecasts range from $11.00 to $30.00. On average, they anticipate Foamix Pharmaceuticals' share price to reach $17.00 in the next year. This suggests a possible upside of 428.0% from the stock's current price. View Analyst Price Targets for Foamix Pharmaceuticals.

What is the consensus analysts' recommendation for Foamix Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foamix Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Foamix Pharmaceuticals.

What are Wall Street analysts saying about Foamix Pharmaceuticals stock?

Here are some recent quotes from research analysts about Foamix Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month PT of $15 on shares of FOMX. We expect pipeline success to drive upward earnings revisions to levels not yet reflected in consensus expectations and FOMX’s stock higher. The company has proprietary technology that we think it can successfully leverage to yield a number of new treatments for unmet needs in dermatology (acne, rosacea, among others). Valuation Summary We arrive at our 12-month price target of $15 for FOMX shares by using a blend of EV/EBITDA, DCF and Base-case analysis." (4/2/2019)
  • 2. According to Zacks Investment Research, "Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company's lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel. " (10/8/2018)

Has Foamix Pharmaceuticals been receiving favorable news coverage?

Press coverage about FOMX stock has been trending somewhat positive on Thursday, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Foamix Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.

Who are some of Foamix Pharmaceuticals' key competitors?

What other stocks do shareholders of Foamix Pharmaceuticals own?

Who are Foamix Pharmaceuticals' key executives?

Foamix Pharmaceuticals' management team includes the folowing people:
  • Mr. David T. Domzalski, CEO & Director (Age 52)
  • Mr. Ilan Hadar M.B.A., MBA, CFO & Country Mang. (Age 50)
  • Ms. Mutya Harsch, Gen. Counsel & Chief Legal Officer (Age 44)
  • Dr. Darrell S. Rigel M.D., MS, Consultant (Age 69)
  • Dr. Iain A. Stuart, Chief R&D Officer (Age 46)

Who are Foamix Pharmaceuticals' major shareholders?

Foamix Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Manhattan Co. (0.87%). Company insiders that own Foamix Pharmaceuticals stock include Aharon Schwartz, Alvin D Howard, David Domzalski, Iain Stuart, Matthew T Wiley, Meir Eini, Mutya Harsch, Russell P Elliott and Stanley Hirsch. View Institutional Ownership Trends for Foamix Pharmaceuticals.

Which institutional investors are selling Foamix Pharmaceuticals stock?

FOMX stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co.. Company insiders that have sold Foamix Pharmaceuticals company stock in the last year include Alvin D Howard, David Domzalski, Iain Stuart, Mutya Harsch, Russell P Elliott and Stanley Hirsch. View Insider Buying and Selling for Foamix Pharmaceuticals.

How do I buy shares of Foamix Pharmaceuticals?

Shares of FOMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Foamix Pharmaceuticals' stock price today?

One share of FOMX stock can currently be purchased for approximately $3.22.

How big of a company is Foamix Pharmaceuticals?

Foamix Pharmaceuticals has a market capitalization of $175.06 million and generates $3.60 million in revenue each year. The specialty pharmaceutical company earns $-74,160,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Foamix Pharmaceuticals employs 80 workers across the globe.

What is Foamix Pharmaceuticals' official website?

The official website for Foamix Pharmaceuticals is http://www.foamix.com.

How can I contact Foamix Pharmaceuticals?

Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected]


MarketBeat Community Rating for Foamix Pharmaceuticals (NASDAQ FOMX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  387
MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe FOMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Featured Article: Moving Average (MA)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel